Result: Of note, in the analysed sample, in six patients (2.5%) key
NNRTI mutations not associated with RPV were noted, with
K103N being the most common (five cases, 2.1%), including one case with a triple
K101E/
K103N/
G190A mutation and one with
K103N/
P225H/
K238T.
Discussion: It should be observed that prevalence of the RPV key drug resistance mutations in our sample is higher than that of the
K103N mutation, observed in 2.1% of cases, while etravirine resistance-associated mutations were rare (one sequence each with
K238T and
Y318F).